We previously reported that the incorporation of tissue factor (TF) into cell-derived microvesicles (MVs) is regulated by the phosphorylation of the cytoplasmic domain of TF.
Summary
We previously reported that the incorporation of tissue factor (TF) into cell-derived microvesicles (MVs) is regulated by the phosphorylation of the cytoplasmic domain of TF.
Since the cytoskeletal protein filamin-A is known to bind to the cytoplasmic domain of TF in a phosphorylation-dependent manner, the involvement of filamin-A in the incorporation of TF into MVs was examined. Endothelial cells were transfected to express TF, whereas MDA-MB-231 cells were used to examine endogenously expressed TF. MV release was induced by activating protease-activated receptor-2 (PAR2). Partial suppression of filamin-A expression using two different filamin-A siRNA sequences resulted in significant reductions in the incorporation of TF antigen into MVs as determined by TF-ELISA and western blot analysis, and was reflected in reduced thrombin-generation and FXa-generation capacities of these MVs. Deletion of the cytoplasmic domain of TF also resulted in reduced incorporation of TF into MVs, whereas the suppression of filamin-A expression had no additional effect on the incorporation of truncated TF into MVs. Partial suppression of filamin-A expression had no effect on the number and size distribution of the released MVs. However, >90 % suppression of filamin-A expression resulted in increased MV release, possibly as a result of increased instability of the plasma membrane and underlying cytoskeleton. In conclusion, the presence
Introduction
Tissue factor (TF) is a 47 kDa transmembrane glycoprotein which acts as the initiator of the extrinsic coagulation cascade by binding to coagulation factor VII/FVIIa. Various cells release TF-positive microvesicles (MVs), including endothelial cells (1, 2) , monocytes (3), smooth muscle cells (4) and cancer cells (5) . TF has a small cytoplasmic domain which has no intrinsic kinase activity and which is not required for the procoagulant activity of TF (6) .
However, serine residues 253 and 258 within the cytoplasmic domain of TF are phosphorylated following the activation of protein kinase C (7). Recently we have shown that the incorporation of TF into MVs is regulated by the phosphorylation of serine residues 253 and 258 following PAR2 activation (8) , but the underlying mechanism for this phosphorylation-dependent incorporation of TF into MVs is not known.
The release of MVs from cells is an active process that is induced by increases in intracellular calcium levels, which result in the loss of phospholipid asymmetry within the cell membrane and reorganisation of the cytoskeleton (9,10). The cytoskeletal protein filamin-A maintains the stability and structure of the actin cytoskeleton and also binds to and regulates the function and cellular localisation of many transmembrane and cytosolic proteins (11) .
Filamin-A is a 280 kDa actin-binding protein consisting of an N-terminal actin-binding domain and 24 Ig-like repeats (12) . Filamin-A has been shown to bind to TF through a direct interaction between the cytoplasmic domain of TF and repeats 22-24 within the C-terminus of filamin-A (13) . Furthermore, the phosphorylation of TF at serine residues 253 and 258 has been shown to enhance the binding of TF to filamin-A (13) . Since the phosphorylation of TF at serine 253 also promotes the incorporation of TF into MVs (8) , this study examined whether filamin-A is required for the incorporation of TF into MVs. 
Materials and Methods

Cell
MV isolation and analysis
Cells previously adapted to low serum were washed with PBS and placed in serum-free medium. MVs were isolated from the media by ultracentrifugation as described previously 5 (14) . The concentrations of phosphatidylserine-positive MVs were determined using the Zymuphen MV determination kit (Hyphen BioMed/Quadratech Ltd, Epsom, UK). The TF antigen content of the MV samples was measured using a TF-ELISA (Affinity Biologicals, Ancaster, Canada). The TF content of the MVs was also examined by SDS-PAGE and western blot analysis of MV samples by loading volumes of MV samples adjusted to the number of cells that the MVs were isolated from. TF activity of the MVs was measured using a two-stage chromogenic thrombin generation assay as described previously (15) with a standard curve prepared alongside using lipidated recombinant TF (American Diagnostica, Stamford, USA). TF-dependent thrombin generation was assessed by pre-incubation of MVs with a mouse anti-TF inhibitory antibody (25 µg/ml) (4509, American Diagnostica) or normal mouse IgG (25 µg/ml) (Cell Signaling Technology). The TF activity of the MV samples was also assessed by FXa generation using the Actichrome TF activity kit (American Diagnostica) with a standard curve prepared alongside using lipidated recombinant TF. The number of cells/well from which the MVs were isolated from was determined using crystal violet staining as described previously (14) . The TF antigen content, TF activity and MV densities were normalised to cell numbers and then standardised to TF antigen, TF activity or MV density per million cells.
Nanoparticle tracking analysis
The numbers and size distributions of the isolated MVs were determined by nanoparticle tracking analysis (NTA) using NanoSight LM10 and NTA software (NanoSight Ltd, Amesbury, UK). The Nanosight instrument was calibrated using FluoSpheres® carboxylatemodified microspheres with diameters of 0.1 µm and 1.0 µm (Invitrogen). MV samples were diluted 1:5 in 0.1 µm-filtered PBS and analysed using the NanoSight LM10 by tracking particles over 60 s using a camera level of 12 and shutter speed of 21.26 frames/s. Data were 6 analysed using the NTA software to determine the concentration and size distribution of the MVs.
SDS-PAGE and western blotting
Protein samples (10 µg) were separated by 10 or 12% (w/v) SDS-PAGE and proteins transferred onto nitrocellulose membranes as described previously (14) . The membranes were probed with a rabbit anti-filamin-A antibody (EP2405Y) (Epitomics Inc, CA, USA), a rabbit anti-TF antibody (FL-295) (Santa Cruz Biotechnology), a mouse anti-PAR2 antibody (SAM11) (Santa Cruz Biotechnology) or an anti-GAPDH antibody (Santa Cruz Biotechnology) diluted 1:1000 in TBST followed by horse radish peroxidase (HRP)-conjugated secondary antibodies as described previously (14) . Samples (6 μg of protein) were separated by SDS-PAGE followed by western blot analysis using a rabbit anti-TF antibody (FL-295).
siRNA-mediated knock-down of filamin-A expression
Statistical analysis
Data represent the calculated mean values from the number of experiments stated in the figure legends ± the calculated standard error of the mean. The data were analysed using the statistical package for the social sciences (SPSS). Significance was determined using oneway ANOVA and the Tukey's honestly significance test and values of p<0.05 were considered to be significant.
Results
MDA-MB-231 cells release TF-positive MVs in response to PAR2 activation
We have previously shown that endothelial cells release TF-positive MVs following the activation of protease-activated receptor 2 (PAR2) using a PAR2-agonist peptide (PAR2-AP)
or FXa (8) . Figure 1D) . Incubation of cells with PAR2-AP or FXa resulted in increased incorporation of TF into MVs, whereas PAR1-AP or scrambled peptide had no effect on levels of TF incorporated into the MVs (Supplemental Figure 1E ). PAR2-AP was therefore used throughout this study as a stimulus that induces both the release of MVs and the active incorporation of TF into MVs.
Optimisation of siRNA-mediated suppression of filamin-A expression
Two sets of filamin-A-specific siRNA were used to suppress the expression of filamin-A.
The Figure 3A) . However, activation of cells with PAR2-AP resulted in a 56% increase in plasma membrane-associated TF and a 60% increase in the amount of TF in MVs, whereas total cellular TF expression remained unaltered ( Figure 3B ).
The effect of the suppression of filamin-A expression on MV release
The release of phosphatidylserine-positive MVs from endothelial cells and MDA-MB-231 cells as measured using the Zymuphen assay was not significantly reduced by the suppression of filamin-A expression (Figures 4A-D) . Total numbers and size distributions of the released MVs as determined using nanoparticle tracking analysis, were also not significantly affected by the suppression of filamin-A expression ( Figure 4E ). The size distribution of all MV samples ranged from 60-500 nm in diameter with two main populations observed, the major population with a peak size of 100 nm and the smaller population with a peak size of 300-400 nm (Supplemental Figure 5) . Analysis of MV samples isolated from control cells and not subjected to ultracentrifugation revealed a similar size distribution compared to MVs isolated by ultracentrifugation (Supplemental Figure 5D) , and no particles were detected in the 0.1 μm-filtered PBS used for resuspending MVs (Supplemental Figure 5E ). The exosome marker (13), filamin-A may serve to localise TF to specific sites on the cell surface for subsequent incorporation and release into MVs in response to PAR2 activation. Filamin-A and TF have been shown to co-localise in lipid rafts during cell migration (22) , and it has been suggested that MVs originate from lipid rafts (3, 23) . It is therefore possible that filamin-A regulates the accumulation of TF into lipid rafts for subsequent incorporation into MVs. Interestingly, the suppression of filamin-A expression did not alter levels of cell surface TF expression in nonactivated cells ( Figure 3A ), indicating that filamin-A is not required for the normal turnover of TF at the cell surface. However, in agreement with a previous report (24) , the activation of PAR2 resulted in the translocation of TF to the plasma membrane ( Figure 3B ), a process which is believed to precede TF release into MVs (25) . Filamin-A has been shown to regulate the transport of receptors to the cell surface, such as the transport of GPIbα from the endoplasmic reticulum to the surface of platelets (26, 27) . Therefore, the possible role of filamin-A in PAR2-induced translocation of TF to the cell surface for subsequent incorporation of TF into MVs requires further investigation.
Interestingly, deletion of the cytoplasmic domain of TF also resulted in reduced incorporation of TF into MVs, and the suppression of filamin-A expression had no further effect on the incorporation of cytoplasmic domain-deleted TF ( Figure 1F ). This shows that both the cytoplasmic domain of TF and filamin-A are required for the incorporation of TF into MVs.
This appears to contradict the study by Schecter et al (2000) which showed that smooth 13 muscle cells release truncated and wild-type TF into MVs at similar levels (4). However, this discrepancy may be due to differences between the TF constructs used in these two studies.
In the study by Schecter et al, both the cytoplasmic and transmembrane domains of TF were replaced with the C-terminus of the GPI-anchored protein decay-accelerating factor, resulting in the extracellular domain of TF being anchored to the cell surface through a GPI-link. GPIanchored proteins are known to localise to cholesterol-rich microdomains and lipid rafts (28, 29) . Since MVs are thought to originate from lipid rafts (3, 23) , the GPI-anchored form of TF is likely to be preferentially targeted to sites of MV release and incorporated into MVs at similar levels to wild-type TF. In fact, it has been shown that decay-accelerating factor is spontaneously released by cells under normal culture conditions (30) . In contrast, in our study This is the first study to demonstrate that filamin-A is required for the incorporation of TF into MVs following PAR2 activation. Importantly, this seems to be independent of the process of MV release in response to PAR2 activation, and suggests a mechanism by which TF is actively incorporated into MVs. Since the N-terminal actin-binding domain of filamin-
A binds directly to actin, it is possible that the filamin-A-dependent incorporation of TF into
MVs is mediated by filamin-A linking TF to the actin cytoskeleton. Additionally, filamin-A may act as a scaffolding protein mediating the activation of signalling proteins (11) necessary for the incorporation of TF into MVs. Furthermore, while PAR2 activation was used as a stimulus to induce MV formation and release, the protein composition of MVs is known to be dependent on the activating stimulus (32) . Therefore, whether stimuli such as inflammatory cytokines and thrombin which induce endothelial cells to release MVs (9,21) also modulate the incorporation of TF into MVs through a filamin-A-dependent mechanism remains to be elucidated. In conclusion, this study proposes a novel mechanism by which TF is actively incorporated into MVs by a process requiring filamin-A, and is independent of the process of MV formation and release.
activities of MDA-MB-231-derived MVs were also determined using a FXa-generation assay (n=3). *=p<0.05 vs. control siRNA. and total membrane fractions were prepared using the plasma membrane isolation kit. Equal quantities of protein (6 µg) for each sample were separated by SDS-PAGE and membranes were probed using a rabbit anti-TF antibody. 
